Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Xu, Kun; An, Yaling; Li, Qunlong; Huang, Weijin; Han, Yuxuan; Zheng, Tianyi; Fang, Fang; Liu, Hui; Liu, Chuanyu; Gao, Ping; Xu, Senyu; Liu, Xueyuan; Zhang, Rong; Zhao, Xin; Liu, William J.; Bi, Yuhai; Wang, Youchun; Zhou, Dongming; Wang, Qinghan; Hou, Wenli; Xia, Qianfeng; Gao, George F.; Dai, Lianpan
• Is Part Of: Emerging microbes & infections. Volume 10:Issue 1(2021)
• Page Start: 1574
• Page End: 1588
• Publication Date: 2021-01-01
• Subjects: COVID-19 -- SARS-CoV-2 -- vaccine -- adenovirus -- antibody -- immune response; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2021.1959270
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: A safe and effective vaccine is urgently needed to control the unprecedented COVID-19 pandemic. Four adenovirus-vectored vaccines expressing spike (S) protein have been approved for use. Here, we generated several recombinant chimpanzee adenovirus (AdC7) vaccines expressing S, receptor-binding domain (RBD), or tandem-repeat dimeric RBD (RBD-tr2). We found vaccination via either intramuscular or intranasal route was highly immunogenic in mice to elicit both humoral and cellular immune responses. AdC7-RBD-tr2 showed higher antibody responses compared to either AdC7-S or AdC7-RBD. Intranasal administration of AdC7-RBD-tr2 additionally induced mucosal immunity with neutralizing activity in bronchoalveolar lavage fluid. Either single-dose or two-dose mucosal administration of AdC7-RBD-tr2 protected mice against SARS-CoV-2 challenge, with undetectable subgenomic RNA in lung and relieved lung injury. AdC7-RBD-tr2-elicted sera preserved the neutralizing activity against the circulating variants, especially the Delta variant. These results support AdC7-RBD-tr2 as a promising COVID-19 vaccine candidate.